<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02387294</url>
  </required_header>
  <id_info>
    <org_study_id>FABNovo-H-16</org_study_id>
    <nct_id>NCT02387294</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection for Children and Adolescents</brief_title>
  <official_title>Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection (Trivalent, Seasonal Influenza Vaccine, Active Ingredient Content: 6 μg HA/Strain/0.5 ml) for Children and Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fluart Innovative Vaccine Ltd, Hungary</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fluart Innovative Vaccine Ltd, Hungary</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection (trivalent,&#xD;
      seasonal influenza vaccine, active ingredient content: 6 μg HA/strain/0.5 ml) for Children&#xD;
      and Adolescents.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY PERIOD:&#xD;
&#xD;
      Length of enrollment: 2 weeks (estimated) Participation per subject: max. 1 month&#xD;
&#xD;
      OBJECTIVES:&#xD;
&#xD;
      Immunogenicity Objectives:&#xD;
&#xD;
      To assess immunogenicity of a single intramuscular injection of Fluval AB Novo suspension for&#xD;
      injection (trivalent, seasonal influenza vaccine, active ingredient content: 6 μg HA/0.5 ml&#xD;
      of seasonal A/H1N1, A/H3N2 and B influenza antigens each), as measured by haemagglutination&#xD;
      inhibition (HI) test.&#xD;
&#xD;
      Safety and Tolerability Objectives:&#xD;
&#xD;
      To evaluate safety and tolerability (incidence of adverse events) of a single intramuscular&#xD;
      injection of Fluval AB Novo suspension for injection.&#xD;
&#xD;
      CLINICAL PHASE:&#xD;
&#xD;
      Phase III&#xD;
&#xD;
      TYPE:&#xD;
&#xD;
      Interventional, prevention&#xD;
&#xD;
      DESIGN:&#xD;
&#xD;
      Non-controlled, open, multi-centre&#xD;
&#xD;
      METHODS:&#xD;
&#xD;
      In this uncontrolled, open, multi-centre immunogenicity and tolerability study subjects were&#xD;
      enrolled into two groups according to age:&#xD;
&#xD;
      Age group 1: children (3-11 years): single intramuscular injection of Fluval AB Novo 0.25 ml&#xD;
      suspension for injection; Age group 2: adolescents (12-18 years): single intramuscular&#xD;
      injection of Fluval AB Novo 0.5 ml suspension for injection; Subjects were observed for 30&#xD;
      minutes after the injection for any immediate reactions.&#xD;
&#xD;
      All adolescent subjects aged 12 to 18 years and the legitimate representatives of all&#xD;
      volunteers were requested to complete a Diary Card (DC) to record local reactions (injection&#xD;
      site pain, erythema, swelling, induration, numbness, sensitivity and haematoma) and systemic&#xD;
      reactions (fever, shivering, headache, malaise, fatigue, sweating, nausea, myalgia,&#xD;
      arthralgia, dizziness and urticaria) starting on the day of vaccination on Visit 1 (Day 0)&#xD;
      until 7 days following that.&#xD;
&#xD;
      All adverse events were collected during the period of Visit 1 (Day 0) to Visit 2 (between&#xD;
      Day 21 and Day 28); Serum samples for immunogenicity assays were collected immediately before&#xD;
      immunization on Visit 1 (Day 0) and on Visit 2 (between Day 21 and Day 28) in all subjects.&#xD;
      Immunogenicity were evaluated by HI test.&#xD;
&#xD;
      INVESTIGATIONAL MEDICINAL PRODUCT:&#xD;
&#xD;
      Fluval AB Novo suspension for injection (trivalent, seasonal influenza vaccine, active&#xD;
      ingredient content: 6 μg HA/0.5 ml of seasonal A/H1N1, A/H3N2 and B influenza antigens each)&#xD;
      with aluminium phosphate gel adjuvant.&#xD;
&#xD;
      Lot No.: FL-N-05/13&#xD;
&#xD;
      CONCOMITANT VACCINES:&#xD;
&#xD;
      No concomitant vaccination is permitted for the duration of the study except for&#xD;
      post-exposure vaccination in a medical emergency (e.g. tetanus, rabies, hepatitis).&#xD;
&#xD;
      STUDY POPULATION:&#xD;
&#xD;
      Considering approximately 17% of drop-out (one participant out of six), in total 120 subjects&#xD;
      (60 subjects in each age group) were enrolled in order to achieve at least 100 evaluable&#xD;
      subjects (50 subjects in each age group).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>parallel-group study in two paediatric age groups</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in Geometric Mean Titre Ratio, A/H1N1 Strain</measure>
    <time_frame>21-28 days after vaccination</time_frame>
    <description>Ratio of Day 0 and Day 21-28 antihaemagglutination inhibition titres&#xD;
Requirement: &gt; 2.5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Increase in Geometric Mean Titre Ratio, A/H3N2 Strain</measure>
    <time_frame>21-28 days after vaccination</time_frame>
    <description>Ratio of Day 0 and Day 21-28 antihaemagglutination inhibition titres&#xD;
Requirement: &gt; 2.5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Increase in Geometric Mean Titre Ratio, B Strain</measure>
    <time_frame>21-28 days after vaccination</time_frame>
    <description>Ratio of Day 0 and Day 21-28 antihaemagglutination inhibition titres&#xD;
Requirement: &gt; 2.5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion, A/H1N1 Strain</measure>
    <time_frame>21-28 days after vaccination</time_frame>
    <description>Proportion of subjects seroconverted or had a significant increase in titres&#xD;
Requirement: &gt; 40 %</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion, A/H3N2 Strain</measure>
    <time_frame>21-28 days after vaccination</time_frame>
    <description>Proportion of subjects seroconverted or had a significant increase in titres&#xD;
Requirement: &gt; 40 %</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion, B Strain</measure>
    <time_frame>21-28 days after vaccination</time_frame>
    <description>Proportion of subjects seroconverted or had a significant increase in titres&#xD;
Requirement: &gt; 40 %</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroprotection, A/H1N1 Strain</measure>
    <time_frame>21-28 days after vaccination</time_frame>
    <description>Proportion of subjects seroprotected&#xD;
Requirement: &gt; 70 %</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroprotection, A/H3N2 Strain</measure>
    <time_frame>21-28 days after vaccination</time_frame>
    <description>Proportion of subjects seroprotected&#xD;
Requirement: &gt; 70 %</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroprotection, B Strain</measure>
    <time_frame>21-28 days after vaccination</time_frame>
    <description>Proportion of subjects seroprotected&#xD;
Requirement: &gt; 70 %</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Human Influenza</condition>
  <arm_group>
    <arm_group_label>Age group 1: children (3-11 years)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Vaccination with Fluval AB Novo suspension for injection.&#xD;
Dosage: Half dose of a single dose (0.25 ml) vaccine, administered intramuscularly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age group 2: adolescents (12-18 years)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Vaccination with Fluval AB Novo suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vaccination with Fluval AB Novo suspension for injection, half dose of a single intramuscular dose (0.25 ml)</intervention_name>
    <description>vaccination</description>
    <arm_group_label>Age group 1: children (3-11 years)</arm_group_label>
    <other_name>Fluval AB Novo suspension for injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vaccination with Fluval AB Novo suspension for injection, single intramuscular dose (0.5 ml)</intervention_name>
    <description>vaccination</description>
    <arm_group_label>Age group 2: adolescents (12-18 years)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children aged 3 to 11 years, adolescents aged 12 to 18 years from both sexes;&#xD;
&#xD;
          -  Are in good health (as determined by vital signs and existing medical condition) or&#xD;
             are in stable medical condition. Subjects will not be excluded with known adequately&#xD;
             treated clinically significant organ or systemic diseases (e.g. asthma or diabetes),&#xD;
             such that, in the opinion of the investigator, the significance of the disease will&#xD;
             not compromise the subject's participation in the study;&#xD;
&#xD;
          -  Female volunteers of childbearing potential with a negative result from the urine&#xD;
             pregnancy test prior to vaccination who agrees to use an acceptable contraception&#xD;
             method or abstinence throughout the trial and not become pregnant for the duration of&#xD;
             the study;&#xD;
&#xD;
          -  Capability of adolescent participants aged 12 to 18 years and the legitimate&#xD;
             representative of all volunteers to understand and comply with planned study&#xD;
             procedures;&#xD;
&#xD;
          -  Adolescent participants aged 12 to 18 years and the legitimate representative of all&#xD;
             volunteers provide written Informed Consent (IC) prior to initiation of study&#xD;
             procedures;&#xD;
&#xD;
          -  Absence of existence of any exclusion criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy, breast feeding or positive urine pregnancy test at baseline prior to&#xD;
             vaccination. Female subjects who are able to bear children but not willing to use an&#xD;
             acceptable contraception method for the duration of the study.&#xD;
&#xD;
          -  Known hypersensitivity to eggs, thiomersal, formaldehyde, gentamycin, ciprofloxacin,&#xD;
             neomycin, vancomycin or any other component of the vaccine;&#xD;
&#xD;
          -  History of Guillain-Barré syndrome;&#xD;
&#xD;
          -  History of neurological symptoms or signs, or anaphylactic shock following&#xD;
             administration of any vaccine;&#xD;
&#xD;
          -  Serious disease, such as cancer, autoimmune disease, advanced arteriosclerotic&#xD;
             disease, complicated diabetes mellitus, acute or progressive hepatic disease, acute or&#xD;
             progressive renal disease, congestive heart failure;&#xD;
&#xD;
          -  Immunosuppressive therapy within 36 months prior to vaccination;&#xD;
&#xD;
          -  Concomitant corticosteroid therapy, including high-dose inhaled corticosteroids;&#xD;
&#xD;
          -  Receipt of immunostimulants,&#xD;
&#xD;
          -  Receipt of parenteral immunoglobulin, blood products and/or plasma derivate within 3&#xD;
             months prior to vaccination;&#xD;
&#xD;
          -  Suspected or known HIV, HBV or HCV infection;&#xD;
&#xD;
          -  Acute disease and/or axillary temperature ≥37oC within 3 days prior to vaccination;&#xD;
&#xD;
          -  Vaccine therapy within 4 weeks prior to vaccination;&#xD;
&#xD;
          -  Influenza vaccination (any kind) within 6 months prior to vaccination;&#xD;
&#xD;
          -  Experimental drug therapy within 4 weeks prior to vaccination;&#xD;
&#xD;
          -  Concomitant participation in another clinical study;&#xD;
&#xD;
          -  Any condition which, in the opinion of the investigator, may interfere with the&#xD;
             evaluation of the study;&#xD;
&#xD;
          -  Past or current psychiatric disease of the volunteer or the legitimate representative&#xD;
             that upon judgement of the investigator may have effect on the objective&#xD;
             decision-making of the volunteer;&#xD;
&#xD;
          -  Alcohol or drug abuse of the participant or the legitimate representative.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>October 16, 2014</study_first_submitted>
  <study_first_submitted_qc>March 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2015</study_first_posted>
  <results_first_submitted>February 17, 2021</results_first_submitted>
  <results_first_submitted_qc>February 17, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 11, 2021</results_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunogenicity</keyword>
  <keyword>reduced dose</keyword>
  <keyword>Phase III</keyword>
  <keyword>tolerability</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Age Group 1: Children (3-11 Years)</title>
          <description>Intervention: Vaccination with Fluval AB Novo&#xD;
Dosage: half of the single dose</description>
        </group>
        <group group_id="P2">
          <title>Age Group 2: Adolescents</title>
          <description>Intervention: Vaccination with Fluval AB Novo&#xD;
Dosage: single dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Age Group 1: Children (3-11 Years)</title>
          <description>Intervention: Vaccination with Fluval AB Novo suspension for injection.&#xD;
Dosage: Half dose of a single dose (0.25 ml) vaccine, administered intramuscularly.</description>
        </group>
        <group group_id="B2">
          <title>Age Group 2: Adolescents (12-18 Years)</title>
          <description>Intervention: Vaccination with Fluval AB Novo suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Age at the time of enrolment</description>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.93" spread="2.65"/>
                    <measurement group_id="B2" value="14.38" spread="1.54"/>
                    <measurement group_id="B3" value="11.16" spread="3.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Increase in Geometric Mean Titre Ratio, A/H1N1 Strain</title>
        <description>Ratio of Day 0 and Day 21-28 antihaemagglutination inhibition titres&#xD;
Requirement: &gt; 2.5</description>
        <time_frame>21-28 days after vaccination</time_frame>
        <population>PP population (subjects whose antihaemagglutination inhibition titres are available both Day 0 and Day 21-28 visits)</population>
        <group_list>
          <group group_id="O1">
            <title>Age Group 1: Children (3-11 Years)</title>
            <description>Intervention: Vaccination with Fluval AB Novo suspension for injection.&#xD;
Dosage: Half dose of a single dose (0.25 ml) vaccine, administered intramuscularly.</description>
          </group>
          <group group_id="O2">
            <title>Age Group 2: Adolescents</title>
            <description>Intervention: Vaccination with Fluval AB Novo suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Increase in Geometric Mean Titre Ratio, A/H1N1 Strain</title>
          <description>Ratio of Day 0 and Day 21-28 antihaemagglutination inhibition titres&#xD;
Requirement: &gt; 2.5</description>
          <population>PP population (subjects whose antihaemagglutination inhibition titres are available both Day 0 and Day 21-28 visits)</population>
          <units>Ratio of Day 0 and Day 21-28 titres</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.337" lower_limit="3.432" upper_limit="5.480"/>
                    <measurement group_id="O2" value="4.702" lower_limit="3.595" upper_limit="6.151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Increase in Geometric Mean Titre Ratio, A/H3N2 Strain</title>
        <description>Ratio of Day 0 and Day 21-28 antihaemagglutination inhibition titres&#xD;
Requirement: &gt; 2.5</description>
        <time_frame>21-28 days after vaccination</time_frame>
        <population>PP population (subjects whose antihaemagglutination inhibition titres are available both Day 0 and Day 21-28 visits)</population>
        <group_list>
          <group group_id="O1">
            <title>Age Group 1: Children (3-11 Years)</title>
            <description>Intervention: Vaccination with Fluval AB Novo suspension for injection.&#xD;
Dosage: Half dose of a single dose (0.25 ml) vaccine, administered intramuscularly.</description>
          </group>
          <group group_id="O2">
            <title>Age Group 2: Adolescents (12-18 Years)</title>
            <description>Intervention: Vaccination with Fluval AB Novo suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Increase in Geometric Mean Titre Ratio, A/H3N2 Strain</title>
          <description>Ratio of Day 0 and Day 21-28 antihaemagglutination inhibition titres&#xD;
Requirement: &gt; 2.5</description>
          <population>PP population (subjects whose antihaemagglutination inhibition titres are available both Day 0 and Day 21-28 visits)</population>
          <units>Ratio of Day 0 and Day 21-28 antihaemagg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.982" lower_limit="3.847" upper_limit="6.451"/>
                    <measurement group_id="O2" value="5.993" lower_limit="4.207" upper_limit="8.539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Increase in Geometric Mean Titre Ratio, B Strain</title>
        <description>Ratio of Day 0 and Day 21-28 antihaemagglutination inhibition titres&#xD;
Requirement: &gt; 2.5</description>
        <time_frame>21-28 days after vaccination</time_frame>
        <population>PP population (subjects whose antihaemagglutination inhibition titres are available both Day 0 and Day 21-28 visits)</population>
        <group_list>
          <group group_id="O1">
            <title>Age Group 1: Children (3-11 Years)</title>
            <description>Intervention: Vaccination with Fluval AB Novo suspension for injection.&#xD;
Dosage: Half dose of a single dose (0.25 ml) vaccine, administered intramuscularly.</description>
          </group>
          <group group_id="O2">
            <title>Age Group 2: Adolescents (12-18 Years)</title>
            <description>Intervention: Vaccination with Fluval AB Novo suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Increase in Geometric Mean Titre Ratio, B Strain</title>
          <description>Ratio of Day 0 and Day 21-28 antihaemagglutination inhibition titres&#xD;
Requirement: &gt; 2.5</description>
          <population>PP population (subjects whose antihaemagglutination inhibition titres are available both Day 0 and Day 21-28 visits)</population>
          <units>Ratio of Day 0 and Day 21-28 titres</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.262" lower_limit="3.383" upper_limit="5.370"/>
                    <measurement group_id="O2" value="4.757" lower_limit="3.762" upper_limit="6.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroconversion, A/H1N1 Strain</title>
        <description>Proportion of subjects seroconverted or had a significant increase in titres&#xD;
Requirement: &gt; 40 %</description>
        <time_frame>21-28 days after vaccination</time_frame>
        <population>PP population (subjects whose antihaemagglutination inhibition titres are available both Day 0 and Day 21-28 visits)</population>
        <group_list>
          <group group_id="O1">
            <title>Age Group 1: Children (3-11 Years)</title>
            <description>Intervention: Vaccination with Fluval AB Novo suspension for injection.&#xD;
Dosage: Half dose of a single dose (0.25 ml) vaccine, administered intramuscularly.</description>
          </group>
          <group group_id="O2">
            <title>Age Group 2: Adolescents (12-18 Years)</title>
            <description>Intervention: Vaccination with Fluval AB Novo suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion, A/H1N1 Strain</title>
          <description>Proportion of subjects seroconverted or had a significant increase in titres&#xD;
Requirement: &gt; 40 %</description>
          <population>PP population (subjects whose antihaemagglutination inhibition titres are available both Day 0 and Day 21-28 visits)</population>
          <units>percentage of subjects seroconverted</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.67"/>
                    <measurement group_id="O2" value="66.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroconversion, A/H3N2 Strain</title>
        <description>Proportion of subjects seroconverted or had a significant increase in titres&#xD;
Requirement: &gt; 40 %</description>
        <time_frame>21-28 days after vaccination</time_frame>
        <population>PP population (subjects whose antihaemagglutination inhibition titres are available both Day 0 and Day 21-28 visits)</population>
        <group_list>
          <group group_id="O1">
            <title>Age Group 1: Children (3-11 Years)</title>
            <description>Intervention: Vaccination with Fluval AB Novo suspension for injection.&#xD;
Dosage: Half dose of a single dose (0.25 ml) vaccine, administered intramuscularly.</description>
          </group>
          <group group_id="O2">
            <title>Age Group 2: Adolescents (12-18 Years)</title>
            <description>Intervention: Vaccination with Fluval AB Novo suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion, A/H3N2 Strain</title>
          <description>Proportion of subjects seroconverted or had a significant increase in titres&#xD;
Requirement: &gt; 40 %</description>
          <population>PP population (subjects whose antihaemagglutination inhibition titres are available both Day 0 and Day 21-28 visits)</population>
          <units>percentage of subjects seroconverted</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.33"/>
                    <measurement group_id="O2" value="61.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroconversion, B Strain</title>
        <description>Proportion of subjects seroconverted or had a significant increase in titres&#xD;
Requirement: &gt; 40 %</description>
        <time_frame>21-28 days after vaccination</time_frame>
        <population>PP population (subjects whose antihaemagglutination inhibition titres are available both Day 0 and Day 21-28 visits)</population>
        <group_list>
          <group group_id="O1">
            <title>Age Group 1: Children (3-11 Years)</title>
            <description>Intervention: Vaccination with Fluval AB Novo suspension for injection.&#xD;
Dosage: Half dose of a single dose (0.25 ml) vaccine, administered intramuscularly.</description>
          </group>
          <group group_id="O2">
            <title>Age Group 2: Adolescents (12-18 Years)</title>
            <description>Intervention: Vaccination with Fluval AB Novo suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion, B Strain</title>
          <description>Proportion of subjects seroconverted or had a significant increase in titres&#xD;
Requirement: &gt; 40 %</description>
          <population>PP population (subjects whose antihaemagglutination inhibition titres are available both Day 0 and Day 21-28 visits)</population>
          <units>percentage of subjects seroconverted</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.67"/>
                    <measurement group_id="O2" value="70.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroprotection, A/H1N1 Strain</title>
        <description>Proportion of subjects seroprotected&#xD;
Requirement: &gt; 70 %</description>
        <time_frame>21-28 days after vaccination</time_frame>
        <population>PP population (subjects whose antihaemagglutination inhibition titres are available both Day 0 and Day 21-28 visits)</population>
        <group_list>
          <group group_id="O1">
            <title>Age Group 1: Children (3-11 Years)</title>
            <description>Intervention: Vaccination with Fluval AB Novo suspension for injection.&#xD;
Dosage: Half dose of a single dose (0.25 ml) vaccine, administered intramuscularly.</description>
          </group>
          <group group_id="O2">
            <title>Age Group 2: Adolescents (12-18 Years)</title>
            <description>Intervention: Vaccination with Fluval AB Novo suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection, A/H1N1 Strain</title>
          <description>Proportion of subjects seroprotected&#xD;
Requirement: &gt; 70 %</description>
          <population>PP population (subjects whose antihaemagglutination inhibition titres are available both Day 0 and Day 21-28 visits)</population>
          <units>percentage of subjects seroprotected</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.67"/>
                    <measurement group_id="O2" value="96.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroprotection, A/H3N2 Strain</title>
        <description>Proportion of subjects seroprotected&#xD;
Requirement: &gt; 70 %</description>
        <time_frame>21-28 days after vaccination</time_frame>
        <population>PP population (subjects whose antihaemagglutination inhibition titres are available both Day 0 and Day 21-28 visits)</population>
        <group_list>
          <group group_id="O1">
            <title>Age Group 1: Children (3-11 Years)</title>
            <description>Intervention: Vaccination with Fluval AB Novo suspension for injection.&#xD;
Dosage: Half dose of a single dose (0.25 ml) vaccine, administered intramuscularly.</description>
          </group>
          <group group_id="O2">
            <title>Age Group 2: Adolescents (12-18 Years)</title>
            <description>Intervention: Vaccination with Fluval AB Novo suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection, A/H3N2 Strain</title>
          <description>Proportion of subjects seroprotected&#xD;
Requirement: &gt; 70 %</description>
          <population>PP population (subjects whose antihaemagglutination inhibition titres are available both Day 0 and Day 21-28 visits)</population>
          <units>percentage of subjects seroprotected</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.00"/>
                    <measurement group_id="O2" value="95.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroprotection, B Strain</title>
        <description>Proportion of subjects seroprotected&#xD;
Requirement: &gt; 70 %</description>
        <time_frame>21-28 days after vaccination</time_frame>
        <population>PP population (subjects whose antihaemagglutination inhibition titres are available both Day 0 and Day 21-28 visits)</population>
        <group_list>
          <group group_id="O1">
            <title>Age Group 1: Children (3-11 Years)</title>
            <description>Intervention: Vaccination with Fluval AB Novo suspension for injection.&#xD;
Dosage: Half dose of a single dose (0.25 ml) vaccine, administered intramuscularly.</description>
          </group>
          <group group_id="O2">
            <title>Age Group 2: Adolescents (12-18 Years)</title>
            <description>Intervention: Vaccination with Fluval AB Novo suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection, B Strain</title>
          <description>Proportion of subjects seroprotected&#xD;
Requirement: &gt; 70 %</description>
          <population>PP population (subjects whose antihaemagglutination inhibition titres are available both Day 0 and Day 21-28 visits)</population>
          <units>percentage of subjects seroprotected</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.00"/>
                    <measurement group_id="O2" value="86.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>21-28 days after vaccination</time_frame>
      <desc>Diary card was used by all subjects to record Adverse Events between Day 0-7 (during 7 days after vaccination), afterwards, Adverse Events were recorded on Day 21-28. Serious Adverse Events were reported in 24 hours after its occurrence.</desc>
      <group_list>
        <group group_id="E1">
          <title>Age Group 1: Children (3-11 Years)</title>
          <description>Intervention: Vaccination with Fluval AB Novo suspension for injection.&#xD;
Dosage: Half dose of a single dose (0.25 ml) vaccine, administered intramuscularly.</description>
        </group>
        <group group_id="E2">
          <title>Age Group 2: Adolescents (12-18 Years)</title>
          <description>Intervention: Vaccination with Fluval AB Novo suspension for injection.&#xD;
Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>vomiting</sub_title>
                <description>vomiting</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <description>abdominal pain</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (15.1)">vaccination site pain</sub_title>
                <description>pain at the vaccination site</description>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="60"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>vaccination site erythema</sub_title>
                <description>erythema at the vaccination site</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>vaccination site swelling</sub_title>
                <description>swelling at the vaccination site</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>malaise</sub_title>
                <description>malaise</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>vaccination site induration</sub_title>
                <description>induration at vaccination site</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>vaccination site haematoma</sub_title>
                <description>haematoma at vaccination site</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>chills</sub_title>
                <description>chills</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>pyrexia</sub_title>
                <description>fever</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>hypersensitivity</sub_title>
                <description>allergic reaction</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>pharyngitis</sub_title>
                <description>pharyngitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>helminthic infection</sub_title>
                <description>helminthic infection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>cystitis</sub_title>
                <description>cystitis</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <description>common cold</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>myalgia</sub_title>
                <description>myalgia</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <description>headcahe</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>syncope</sub_title>
                <description>collapsus</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <description>cough</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>oropharyngeal pain</sub_title>
                <description>sore throat</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The disclosure restriction on the PI is that the sponsor in the frames of the general confidentiality agreement is that the PI cannot release any information concenning the study without the prior consent of the sponsor. To further specification is provided.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Zsolt Németh</name_or_title>
      <organization>Fluart Innovative Vaccines Ltd</organization>
      <phone>+3620 ext 4197020</phone>
      <email>info@fluart.hu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

